NASDAQ · CCCCHealthcareBiotechnology

C4 Therapeutics financials

$3.13+0.48%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$35.9M$35.6M$20.8M$31.1M$45.8M$33.2M
Gross profit$35.9M$35.6M$20.8M$31.1M$45.8M$33.2M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%
Operating income-$115.2M-$119.6M-$139.0M-$129.5M-$82.1M-$60.4M
Net income-$105.0M-$105.3M-$132.5M-$128.2M-$83.9M-$66.3M
Net margin−292.1%−296.0%−638.3%−412.2%−183.2%−199.8%
Diluted EPS$-1.27$-1.52$-2.67$-2.62$-1.82$-5.83
EBITDA-$102.5M-$115.4M-$137.2M-$122.0M-$80.6M-$58.8M
Operating cash flow-$98.7M-$65.2M-$106.8M-$105.9M-$87.0M-$67.2M
Free cash flow-$99.3M-$65.3M-$108.5M-$111.4M-$88.2M-$67.9M
Diluted shares82.9M69.4M49.6M48.9M46.0M11.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$74.6M$55.5M$126.6M$29.8M$76.1M$181.7M
Short-term investments$173.9M$189.4M$127.1M$246.4M$233.2M$190.0M
Total debt$0.00$0.00$0.00$11.5M$10.8M$10.1M
Total assets$359.1M$349.6M$376.5M$430.8M$506.8M$400.1M
Total liabilities$102.5M$133.6M$130.3M$141.6M$117.2M$119.3M
Shareholders' equity$256.6M$216.0M$246.1M$289.2M$389.6M$280.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology